Tonbo Imaging India
FinMinutes Deep Business Model & Edge
Tonbo Imaging India Limited is a Bengaluru-headquartered defence technology company specializing in the design, development, and manufacture of advanced electro-optics, thermal imaging, and AI-enabled vision systems for global military, aerospace, and security applications.
What this company actually does — full breakdown ▾
Tonbo Imaging India Limited (formerly Tonbo Imaging India Private Limited, Serial Innovations India Private Limited, and Sarnoff Innovative Technologies Private Limited) provides full-stack Electro-Optical/Infrared (EO/IR) vision systems, thermal imaging sights, driver vision enhancement, and reconnaissance payloads. The company operates an IP-led business model, owning 100% of its electro-optics technology stack (spanning optics, infrared imaging, embedded computing, and AI-enabled control) while outsourcing mass manufacturing to contract partners. In FY26, domestic sales generated ₹ 337.47 crore (93.06% of product sales) and export sales generated ₹ 20.21 crore (5.57%). Product categories comprise Tactical systems (₹ 211.68 crore in FY26) and Platform systems (₹ 144.81 crore in FY26). The company operates delivery and R&D locations in India, Australia (Tonbo Systems Pty Ltd), and Armenia (Tonbo LLC). In Fiscal 2026, consolidated revenue from operations stood at ₹ 362.65 crore (₹ 3,626.48 million) with a Restated Profit After Tax of ₹ 50.88 crore (₹ 508.80 million).
- Tactical Systems — Handheld thermal sights, weapon sights (e.g. Spartan-S), and soldier-worn imaging systems.
- Platform Systems — Gimbal-based payloads, driver vision enhancement for armoured vehicles, and persistent surveillance systems.
Proprietary full-stack Electro-Optical/Infrared IP portfolio (free of ITAR restrictions), high R&D capability (38.35% of workforce in R&D), 94% volume share of India's thermal imaging export market, and long-standing defense customer qualification credentials.
The Offer
Follow the Money — Use of Proceeds
- Carry out the Offer for Sale by the Selling Shareholders and achieve the benefits of listing Equity Shares on the Stock Exchanges
Valuation at the Offer Price
The filing does not print a single headline multiple, so this one is ours: the upper band divided by the latest restated earnings per share — the same arithmetic the “Basis for the Offer Price” section performs. It is struck on pre-issue earnings; where the issue creates new shares, the post-issue multiple is computed in the workings below. The peer group is the one the filing itself names. A premium is not the same thing as expensive and a discount is not the same thing as cheap — the peer table and the reasons sit further down this page.
FinMinutes IPO Score — How It's Built
Transparent, deterministic, computed from the filing — not an opinion. Open any component below to see exactly what it measures and what it is worth. Components with no disclosed input are dropped from the weighting entirely rather than held at an invented neutral, because a constant inside a weighted average is not neutral — it quietly drags every score toward the middle. Weighted across 4 live components.
88% of the designed weighting had real data behind it on this issue. Not yet scored here: Filing Integrity. A lower coverage figure does not mean a worse company — it means we are standing behind less of the picture, and you should read the findings below rather than the headline number.
How this is measured12%
Whether fresh capital actually enters the business. A predominantly offer-for-sale issue is marked down ONLY when the financials are weak. A profitable, cash-rich company selling down is treated as neutral, not penalised, because it does not need the money.
How this is measured32%
Driven by the models battery run on the filing's own restated numbers: the Piotroski fundamental tests (scored out of those we could actually run), the Altman Z-double-prime solvency zone, and the direction of profit across the disclosed period. It is not a single yes/no on last year's profit.
How this is measured10%
The post-issue earnings multiple against the peer median disclosed in the filing. A discount to the median scores well and a premium scores badly. When the filing does not disclose comparable peer multiples, this component is dropped from the weighting rather than held at a made-up neutral.
How this is measured28%
Starts at 100 and loses points for every material finding: 12 for a flagged finding, 4 for a noted one. Two kinds feed it. DERIVED findings are computed from the filed numbers against stated thresholds — operating cash negative while profit is positive, related-party revenue above 15% of total, revenue rising while profit falls, goodwill above 30% of net worth, receivables growing more than 1.3x faster than sales, cash below half of short-term debt. Those are reproducible: the same filing gives the same answer every time, and the rule is printed beside the finding. READ findings come from the forensic sweep of the notes. Contingent liabilities, related-party intensity, customer concentration, litigation, auditor qualifications, statutory dues, promoter funding. Findings that record the ABSENCE of a problem — no litigation pending, an unmodified audit opinion — deduct nothing. This is the component our forensic read drives directly, and it moves most between companies.
3-Year Financial & Growth Trend
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| Revenue (₹ Cr) | 362.65 | 469.08 | 428.19 |
| Net Profit (₹ Cr) | 50.88 | 72.76 | 68.54 |
| PAT Margin | 14.03% | 15.51% | 16.01% |
Revenue Breakdown
- Domestic Sales: 93.06%
- Export Sales: 5.57%
- Other Operating Revenues: 1.37%
Why the numbers moved, in management’s own words
Taken from the Management’s Discussion and Analysis section of the filing. A number tells you what happened; this is the company’s explanation of why, and whether it calls the cause temporary or structural.
| Metric | Move | Management's stated reason | Type |
|---|---|---|---|
| Revenue from operations (FY26 vs FY25) | ↓ 22.7% | Revenue from operations decreased primarily due to timing of delivery schedules and shipment milestones for defence platform systems contracts. | Structural |
| Cost of materials consumed (FY26 vs FY25) | ↓ 23.1% | Cost of materials consumed decreased in line with lower product sales volume. | Structural |
| Employee benefits expense (FY26 vs FY25) | ↑ 11.6% | Employee expenses increased due to R&D engineering additions and annual salary revisions. | Structural |
| Restated PAT (FY26 vs FY25) | ↓ 30.1% | Restated net profit decreased due to lower operating revenue, fixed cost absorption, and higher R&D expenditure. | Structural |
| Operating cash flow (FY26 vs FY25) | ↑ 53.6% | Operating cash flow improved from ₹ -136.12 crore in FY25 to ₹ -63.22 crore in FY26 due to inventory optimization. | Structural |
Headwinds
- Long Procurement Cycles and Delivery Timeline Volatility in Defence Contracts company persistent
Defence procurement involves extended evaluation, field trial, and delivery certification phases, causing quarter-to-quarter revenue lumpiness. - Working Capital Lock-up in Inventory and Unbilled Receivables company persistent
High raw material inventory holding and unbilled receivables lead to negative operating cash flows.
Tailwinds
- Indian DAP 2020 IDDM Mandates and Global Demand for ITAR-Free EO/IR Technologies macro
Government indigenization mandates under Make in India IDDM category and global demand for non-ITAR electro-optics provide strong multi-year order visibility.
Applying, and Who Handles the Allotment
Check allotment status on the registrar’s own portal → We link the registrar directly rather than mirroring the form.
Deep Financials
Revenue, EBITDA and profit are what every listing site prints. Below are the full restated statements as disclosed, the ratios we compute from them, and a DuPont decomposition of the return on equity. A prospectus carries three years, not ten — that is the document’s ceiling, and within it we go as deep as it allows.
Income StatementThe profit and loss as filed, then what we derive from it — kept apart.
Statutory order, exactly as restated in the filing. Finance cost and depreciation sit inside Total Expenses under Ind AS, which is why they are listed among the expense lines here rather than below the total. The expense rows sum to the total. Rows the filing does not disclose separately are omitted rather than left blank.
| Income Statement — as filed (₹ Cr) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Revenue from Operations | 362.65 | 469.08 | 428.19 |
| Other Income | 7.29 | 5.31 | 3.71 |
| Total Income | 369.94 | 474.39 | 431.90 |
| Cost of Materials Consumed | 165.55 | 215.31 | 213.28 |
| Changes in Inventories | 11.97 | -10.70 | 6.66 |
| Employee Benefit Expense | 49.58 | 44.44 | 13.06 |
| Finance Cost | 10.62 | 17.74 | 7.68 |
| Depreciation & Amortisation | 31.34 | 26.59 | 13.40 |
| Other Expenses | 30.92 | 80.97 | 82.88 |
| Total Expenses | 299.98 | 374.35 | 336.94 |
| Profit Before Exceptional Items and Tax | 69.96 | 100.04 | 94.96 |
| Exceptional Items | 0.00 | 0.78 | 0.41 |
| Profit Before Tax | 69.96 | 99.27 | 94.55 |
| Tax Expense | 19.08 | 26.51 | 26.01 |
| Profit After Tax | 50.88 | 72.76 | 68.54 |
| Other Comprehensive Income | 0.02 | 0.01 | 0.10 |
| Total Comprehensive Income | 50.90 | 72.77 | 68.65 |
| EPS - Basic | 9.19 | 13.38 | 62.61 |
| EPS - Diluted | 8.88 | 12.70 | 13.63 |
Balance SheetWhat the company owns, owes, and is worth on paper.
| Balance Sheet (₹ Cr) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Share Capital | 11.46 | 0.73 | 0.30 |
| Reserves & Surplus | 541.70 | 489.41 | 168.99 |
| Net Worth | 553.16 | 490.14 | 230.13 |
| Long-term Borrowings | 0.00 | 0.00 | 15.27 |
| Short-term Borrowings | 116.06 | 78.14 | 81.09 |
| Total Borrowings | 116.06 | 78.14 | 96.36 |
| Trade Payables | 33.44 | 21.15 | 20.35 |
| Current Liabilities | 193.72 | 185.51 | 287.41 |
| Total Liabilities | 229.34 | 236.22 | 344.55 |
| Property, Plant & Equipment | 24.80 | 24.48 | 4.79 |
| Capital Work in Progress | 12.40 | 0.72 | 0.00 |
| Intangible Assets | 162.70 | 165.19 | 183.88 |
| Investments | 0.00 | 0.00 | 0.00 |
| Inventories | 219.49 | 111.14 | 111.69 |
| Trade Receivables | 211.66 | 210.31 | 93.64 |
| Cash & Equivalents | 16.18 | 100.97 | 85.67 |
| Current Assets | 511.55 | 445.80 | 363.12 |
| Total Assets | 782.50 | 726.36 | 574.68 |
Cash FlowWhere the cash actually went. Often the most honest statement of the three.
| Cash Flow (₹ Cr) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Net Cash from Operating Activities | -63.22 | -136.12 | 78.33 |
| Capital Expenditure | 38.96 | 26.67 | 193.51 |
| Net Cash from Investing Activities | -32.27 | -24.69 | -190.17 |
| Net Cash from Financing Activities | 32.19 | 147.06 | 187.81 |
| Net Change in Cash | -63.29 | -13.75 | 75.97 |
Ratio AnalysisProfitability, leverage, liquidity, efficiency and earnings quality — computed by us.
Every ratio below is computed by us from the line items the company disclosed — not copied from anywhere. The arithmetic is standard; the point is that somebody actually did it. Blank cells mean the filing did not disclose the inputs, and we would rather show a gap than invent a number.
| Ratio | FY26 | FY25 | FY24 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin (%) | 30.3 | 30.1 | 26.7 |
| EBIT Margin (%) | 21.8 | 24.5 | 23.6 |
| PAT Margin (%) | 14 | 15.5 | 16 |
| Return on Equity (%) | 9.2 | 14.8 | 29.8 |
| Return on Capital Employed (%) | 12 | 20.5 | 31.2 |
| Return on Assets (%) | 6.5 | 10 | 11.9 |
| Leverage | |||
| Debt / Equity (x) | 0.21 | 0.16 | 0.42 |
| Net Debt / EBITDA (x) | 0.89 | -0.16 | 0.09 |
| Interest Coverage (x) | 7.59 | 6.55 | 13.26 |
| Liquidity | |||
| Current Ratio (x) | 2.64 | 2.4 | 1.26 |
| Quick Ratio (x) | 1.51 | 1.8 | 0.87 |
| Efficiency | |||
| Asset Turnover (x) | 0.46 | 0.65 | 0.75 |
| Receivable Days | 213 | 164 | 80 |
| Inventory Days | 451 | 198 | 185 |
| Payable Days | 69 | 38 | 34 |
| Cash Conversion Cycle (days) | 595 | 324 | 231 |
| Quality of Earnings | |||
| Operating Cash Flow / PAT (x) | -1.24 | -1.87 | 1.14 |
| Accruals Ratio (%) | 14.6 | 28.8 | -1.7 |
| Capex / Depreciation (x) | 1.24 | 1 | 14.44 |
| Inventory and payable days are measured against cost of goods (materials consumed + purchases of stock-in-trade + change in inventories). Receivable days against revenue. | |||
DuPont DecompositionWhy the return on equity is what it is: margin, efficiency, or leverage.
A headline return on equity tells you what. The DuPont decomposition tells you why — whether the return is earned through margin, through asset efficiency, or simply through leverage. Two companies can post an identical ROE for opposite reasons, and only one of them is safe.
| Component | FY26 | FY25 | FY24 |
|---|---|---|---|
| Net Margin (PAT / Revenue) | 14% | 15.5% | 16% |
| Asset Turnover (Revenue / Assets) | 0.46x | 0.65x | 0.75x |
| Equity Multiplier (Assets / Net Worth) | 1.41x | 1.48x | 2.5x |
| = Return on Equity | 9.2% | 14.8% | 29.8% |
| Tax Burden (PAT / PBT) | 0.73x | 0.73x | 0.72x |
| Interest Burden (PBT / EBIT) | 0.87x | 0.85x | 0.93x |
| Operating Margin (EBIT / Revenue) | 22.2% | 24.8% | 23.8% |
Computed from the disclosed statements. Where the filing omits an input, the row is left blank rather than estimated.
Quality of EarningsWhat the statements say when you read them against each other.
What the statements say once you read them against each other. These are observations, not verdicts — every one is arithmetic on the numbers the company itself disclosed, and each is stated so you can go and check it in the filing.
- In FY26 the company reported a profit of 50.88 cr while operating cash flow was NEGATIVE at -63.22 cr. Reported earnings did not convert into cash. This is the single divergence most worth understanding in any set of accounts, and the filing is the place to look for why.
- Receivable days rose from 80 in FY24 to 213 in FY26. The company is booking revenue faster than it is collecting it, which ties up cash and raises the question of who is not paying.
Forensic ModelsBeneish, Altman, Piotroski and the Montier C-score — plus our own final-year check.
Beneish M-Score
M = -1.74An eight-variable model built to detect earnings manipulation, and built to run on exactly two consecutive years — which is what a prospectus gives us. It belongs here more than anywhere: a company about to list has the maximum possible incentive to have dressed up the very years it is about to show you. A score above −1.78 is the threshold at which the model says the accounts merit a closer look. It is a screening signal, not an accusation, and it was calibrated on listed companies elsewhere. Read the eight components, not just the total.
| Component | Value | What it captures |
|---|---|---|
| DSRI Days Sales in Receivables Index (Receivables_t / Sales_t) / (Receivables_t-1 / Sales_t-1) | 1.302 | Above 1 means receivables grew faster than sales. Revenue may be being recognised ahead of collection. |
| GMI Gross Margin Index GrossMargin_t-1 / GrossMargin_t | 0.995 | Above 1 means margins deteriorated. A firm with worsening prospects has more incentive to manipulate. |
| AQI Asset Quality Index AQ_t / AQ_t-1, where AQ = 1 - (CurrentAssets + PPE) / TotalAssets | 0.892 | Above 1 means a rising share of assets is soft (neither current nor fixed) — capitalised costs can hide here. |
| SGI Sales Growth Index Sales_t / Sales_t-1 | 0.773 | Growth is not manipulation. But high-growth firms face more pressure to keep the streak going. |
| DEPI Depreciation Index DepRate_t-1 / DepRate_t, where DepRate = Dep / (Dep + PPE) | 0.933 | Above 1 means assets are being depreciated more slowly — a quiet way to lift reported profit. |
| SGAI SG&A Index (SGA_t / Sales_t) / (SGA_t-1 / Sales_t-1), SGA proxied as employee cost + other expenses | 0.83 | A proxy, because filings rarely break out SG&A cleanly. Read it as a direction, not a precise figure. |
| LVGI Leverage Index Leverage_t / Leverage_t-1, where Leverage = (CurrentLiab + LongTermDebt) / TotalAssets | 0.969 | Above 1 means leverage rose. Debt covenants create pressure to hit numbers. |
| TATA Total Accruals to Total Assets (PAT - CashFromOperations) / TotalAssets | 0.1458 | The gap between reported profit and cash generated. The single heaviest term in the model — and the one that catches profit that never became cash. |
This score is driven primarily by the sales-growth term (SGI). Growth is the one variable in this model that is not itself a manipulation signal — the model treats rapid growth as pressure to keep the streak going, not as evidence of anything. A company that grew revenue several-fold will read high here for that reason alone. The variable that speaks to manipulation directly is TATA (accruals — profit that did not become cash); read that one, and the receivables trend, rather than the headline M.
M = -1.74, above the −1.78 threshold. On this model the accounts merit closer reading. That is a prompt to go to the filing, not a conclusion about it.
Altman Z″-Score (emerging markets)
Z″ = 11.4 · SafeA distress-prediction model. We use the Z″ variant deliberately: the original Z was calibrated on American manufacturers and misleads badly on Indian services companies. Above 2.6 is the safe zone, 1.1 to 2.6 is grey, below 1.1 is the distress zone. Like every model of its kind it is a screen, not a prophecy.
| X1 — Working Capital / Total Assets | 0.406 |
| X2 — Reserves / Total Assets | 0.692 |
| X3 — EBIT / Total Assets | 0.103 |
| X4 — Net Worth / Total Liabilities | 2.412 |
| Z″ = 3.25 + 6.56·X1 + 3.26·X2 + 6.72·X3 + 1.05·X4 | 11.4 |
X2 is meant to read retained earnings. The filing reports Other Equity, which also holds securities premium paid in by investors, so X2 here runs on reserves and reads higher than true retained earnings would. The more premium the company has raised before listing, the more Z″ is flattered.
Piotroski F-Score (adapted)
3 / 8Nine yes-or-no tests of fundamental strength — except we run eight. One of the original nine asks whether the company issued new shares, which is plainly absurd to ask of a company whose entire purpose at this moment is to issue shares. We drop that test, and we would rather tell you that than quietly fudge it.
- ✓Positive return on assets
- ✗Positive operating cash flow
- ✗Return on assets improving
- ✗Cash flow exceeds profit (quality of earnings)
- ✗Long-term leverage decreasing
- ✓Current ratio improving
- ✓Gross margin improving
- ✗Asset turnover improving
Montier C-Score
3 of 6 signsSix yes-or-no signs that reported profit may be running ahead of the business, from James Montier’s 2008 screen, read here for FY26 against FY25. Each is a direction in the statements, not a judgement. Several together are a reason to read the accounting policies and notes closely; none on its own means anything is wrong, and growing companies trip some of them honestly.
- ○Gap between profit and operating cash flow widening · PAT − CFO: ₹208.9 cr in FY25, ₹114.1 cr in FY26
- ●Receivable days rising · 164 days in FY25, 213 days in FY26
- ●Inventory days rising · 198 days in FY25, 451 days in FY26 (on cost of goods)
- ●Other current assets rising against revenue · 5.0% of revenue in FY25, 17.7% in FY26 (current assets less cash, receivables and inventory)
- ○Depreciation falling against fixed assets · 108.6% of net block in FY25, 126.4% in FY26
- ○Total assets growing more than 10% a year · 7.7% in FY26
The Final-Year Check
oursNot from any textbook. The hockey stick in the last year before a filing is the oldest pattern in this business, and nobody publishes it. So we measure it: how the final disclosed year compares with the years behind it. Real acceleration looks exactly the same on the page as a flattering one — which is precisely why it is worth naming rather than assuming either way.
- Cash conversion fell sharply in the final year: operating cash flow was -1.24x profit in FY26, against -1.87x in FY25. Profit rose; the cash behind it did not follow at the same rate.
Ratios Nobody Prints
- Contingent liabilities / Net worth: 12.4%
Contingent liabilities of 68.71 cr against a net worth of 553.16 cr — 12.4% of what the company is worth on paper. These are obligations that sit off the balance sheet but could land on it. What they consist of matters as much as the size: a corporate guarantee to a subsidiary is a different animal from a disputed tax demand, and the filing says which. - Related-party revenue / Total revenue: 0%
0% of revenue in FY26 came from entities connected to the promoters. Revenue you sell to yourself is not the same as revenue you won in the market. - Cash / Short-term borrowings: 0.14x
Short-term borrowings of 116.06 cr against cash of 16.18 cr. Debt that must be refinanced within a year is only comfortable while lenders stay comfortable. - Promoter remuneration / PAT: 10.2%
Managerial remuneration to the promoter group was 5.21 cr against a profit of 50.88 cr. This is a legitimate cost — but it is also a route by which value leaves a company before it ever reaches a minority shareholder.
What the Price RequiresThe profit the offer price needs, at three hurdle rates. A restatement of the price, not a view on it.
At the upper band of ₹700.00, the market value is ₹4,011 cr. A buyer who wants a given return each year from a business that never grows needs annual profit of market value × that return. The three rates are round hurdle rates, not this company’s cost of capital, so pick the one that is yours. The years columns assume profit compounds from the FY26 figure and the price stands still. None of this is a forecast, a fair value or a target.
| Hurdle rate | Profit the price needs | × FY26 profit | Years at 15% growth | Years at 25% growth |
|---|---|---|---|---|
| 10% a year | ₹401 cr | 7.9x | 14.8 | 9.3 |
| 12% a year | ₹481 cr | 9.5x | 16.1 | 10.1 |
| 14% a year | ₹562 cr | 11.0x | 17.2 | 10.8 |
- Earnings yield at the upper band: 1.27% (FY26 profit ÷ market value).
- Free cash flow yield: -2.55% (operating cash flow less capital expenditure, −₹102 cr, ÷ market value).
The Formula NotebookEvery number above, with the working shown. Check us.
Every number we publish, with the working shown. The formula, the same formula with this company’s actual figures put into it, the answer, and what it is for. Check us. That is the point.
PAT ÷ Net Worth50.88 ÷ 553.16What the company earned on the money shareholders have in it. The headline measure of return — and the one the DuPont section takes apart.
EBIT ÷ (Net Worth + Total Borrowings)80.58 ÷ (553.16 + 116.06) = 80.58 ÷ 669.22Return on ALL the capital in the business, borrowed as well as owned. Unlike ROE, it cannot be flattered by taking on debt.
EBITDA ÷ Revenue111.92 ÷ 362.65Operating profitability before the effects of debt, tax and depreciation. What the business earns from the act of trading.
Total Borrowings ÷ Net Worth116.06 ÷ 553.16How much the company has borrowed against what it owns. High is not automatically bad — ask whether the borrowing is being serviced comfortably.
EBIT ÷ Finance Cost80.58 ÷ 10.62How many times over operating profit covers the interest bill. Below about 2x, a meaningful share of what the business earns is going to lenders rather than owners.
(Trade Receivables ÷ Revenue) × 365(211.66 ÷ 362.65) × 365How long the company waits to be paid. Rising receivable days mean revenue is being booked faster than it is collected — which is where a great many accounting problems begin.
Inventory Days + Receivable Days − Payable Days451 + 213 − 69How long cash is tied up in the operating cycle before it comes back. The longer it is, the more working capital the business must fund.
Cash from Operations ÷ PAT-63.22 ÷ 50.88Did the profit turn into cash? Profit is an opinion; cash is a fact. When this sits well below 1x for long, the two are drifting apart, and the filing is where you find out why.
(PAT − Cash from Operations) ÷ Total Assets(50.88 − -63.22) ÷ 782.50 = 114.10 ÷ 782.50The share of reported profit that exists on paper rather than in the bank. It is also the heaviest single term in the Beneish model, for good reason.
Price × Post-issue Shares₹700.00 × 57,300,000 sharesWhat the whole company is being valued at, if the issue prices at the top of the band.
Market Cap + Total Borrowings − Cash4,011.00 + 116.06 − 16.18What it would actually cost to buy the whole business: you take on its debt and you get its cash. This is the number a buyer cares about, and it is the reason a P/E on its own can mislead.
Enterprise Value ÷ EBITDA4,110.88 ÷ 111.92The multiple that includes debt. Two companies on the same P/E — one debt-free, one heavily borrowed — are not the same investment, and only this number tells you so.
Market Cap ÷ PAT4,011.00 ÷ 50.88The familiar multiple. Useful, but blind to debt — read it alongside EV/EBITDA, never instead of it.
Offer price ÷ weighted average cost of acquisition₹700.00 ÷ ₹2.00Every offer document must disclose the weighted average cost of acquisition for shares issued or transferred over the preceding one, eighteen and thirty-six months. Early capital takes real risk and a large multiple built over years is ordinary. A steep step-up inside a short window is the one that deserves a second look. What it means is yours to decide; the arithmetic is the filing’s own.
EBIT × (1 − tax rate) ÷ (Net Worth + Debt − Cash)NOPAT ÷ Invested CapitalWhat the business earns on the capital actually at work in it. We do not compare this to a cost of capital: that would need a beta, an unlisted company has none, and inventing one would be theatre.
Latest full-year PAT ÷ market value₹50.88 cr ÷ ₹4,011.00 crThe P/E turned upside down: what each rupee of market value earns today. Set it against what you could earn elsewhere; the gap is what growth has to make up.
(Operating cash flow − capital expenditure) ÷ market value₹-102.18 cr ÷ ₹4,011.00 crCash left after the company pays for its own investment, against the price of the whole company. Profit can be shaped by accounting choices; this is harder to shape.
Workspace
The numbers are already loaded. Move the offer price and watch every multiple move with it. Set your own growth and margin and see what they imply two years out. These are your assumptions, not our forecast — we have no view on what this company will earn, and the moment we published one we would be doing something we are not registered to do. What we can do is put the arithmetic in front of you and get out of the way.
Price defaults to the top of the band. Margin defaults to what the company actually reported in FY26.
Projections are arithmetic on the inputs you typed. They are not a forecast, not a recommendation, and not a view on whether this offer is worth taking. Educational only.
Institutional Alpha: DRHP Deep Dive
According to the F&S Report, global and Indian defense electronics markets are driven by modern battlefield digitization, network-centric warfare, and demand for ITAR-free electro-optical/infrared (EO/IR) technologies. Tonbo Imaging represents a leading Indian exporter of thermal imaging systems, accounting for 94% of India's thermal imaging export volume between FY24 and FY26.
100% Secondary Offer for Sale with Zero Primary Equity Capital Inflow
The IPO is structured entirely as an Offer for Sale of 12,174,046 Equity Shares by Selling Shareholders including Promoters, CEAQ India, CEAQ Singapore, and Artiman entities. The company receives no fresh issue proceeds.
Source: p.1, p.84, p.124Dominant Thermal Imaging Export Market Position with ITAR-Free IP
Tonbo Imaging commands 94% volume share of India's thermal imaging exports between FY24 and FY26. Owning 100% of its full-stack electro-optics IP portfolio free of US ITAR restrictions allows seamless export across 12+ international jurisdictions.
Source: p.231, p.257, p.278IP Acquisition from Related Party CEAQ Singapore Eliminating Royalty Drag
Tonbo acquired the complete electro-optics IP stack from related party CEAQ Singapore for ₹ 183.19 crore (USD 22.25 million equivalent) in March 2024, eliminating perpetual 10-12% royalty payments and consolidating technology ownership.
Source: p.257, p.429Shareholding, Syndicate & Leadership
Leadership & Skin in the Game
Leadership: Arvind Kondangi Lakshmikumar
Litigation: ₹ 0.83 crore (₹ 8.32 million) in Goods and Services Tax proceedings pending against the Company.
Auditor / RPT Flags: None; Auditor examination reports contain unmodified opinions for FY24-FY26.
Peers & Valuation
| Company | P/E | P/B | RoE | Margin |
|---|---|---|---|---|
| Paras Defence and Space Technologies Limited | — | — | — | 18.16 |
| Data Patterns (India) Limited | — | — | 17 | 28.48 |
| Astra Microwave Products Limited | — | — | — | 16.6 |
| Zen Technologies Limited | — | — | — | 28.19 |
| Bharat Electronics Limited | — | — | — | 21.52 |
At the ₹700 upper band, the issue is priced at 78.8x earnings — a 3% discount to the peer median of 81.6x. This is the arithmetic of the price band against the peers the filing itself lists; it is not a view on whether the offer is worth taking.
Electro-Optics & Defence Electronics Vitals
The operating metrics that actually price this business — the ones a generic IPO page skips. Straight from the filing.
| Metric | Value | Detail |
|---|---|---|
| Thermal Imaging Export Volume Share | 94.0% | Tonbo share of India's total thermal imaging exports volume between FY24 and FY26 |
| Tactical Systems Revenue Share | 58.37% | share of FY26 product sales revenue (₹ 211.68 crore) |
| Platform Systems Revenue Share | 39.93% | share of FY26 product sales revenue (₹ 144.81 crore) |
| R&D Workforce Share | 38.35% | share of total employees engaged in R&D as of March 31, 2026 |
Source: p.231, p.257, p.278, p.423
🔍 Forensic Findings — What the Footnotes Say
Findings from across the filing — the notes, MD&A, related-party disclosures, contingent liabilities, CARO and litigation, alongside the risk section itself. Each carries where it was found, so you can see which were buried and which were disclosed. Findings marked derived are computed from the filed numbers against a stated rule, shown beside them.
Tonbo Imaging India Limited recorded negative cash flows from operating activities of ₹ -63.22 crore in FY26 and ₹ -136.12 crore in FY25 due to working capital lock-up in inventories (₹ 219.49 crore) and trade receivables (₹ 211.66 crore).
p.90, p.433SEBI received complaints alleging non-disclosure of sole supplier dependence, IDDM threshold claims, and IP acquisitions from related party CEAQ Technologies. The company and BRLMs filed detailed responses refuting all allegations.
p.39, p.42Company acquired intellectual property worth ₹ 183.19 crore (USD 22.25 million equivalent) from related party CEAQ Singapore in March 2024, eliminating ongoing 10-12% royalty payments.
p.257, p.429The IPO consists 100% of an Offer for Sale of 12,174,046 Equity Shares with zero primary issue proceeds received by the Company.
p.1, p.84₹ 0.83 crore (₹ 8.32 million) in Goods and Services Tax proceedings pending against the Company.
p.1, p.114, p.322, p.366Operating cash flow was negative ₹63.22 cr in FY26 while the company reported a profit after tax of ₹50.88 cr. Profit that does not arrive as cash has to be funded from somewhere else.
rule: CFO<0 & PAT>0Goodwill and intangibles are 29.4% of net worth.
rule: intangibles 15-30% of net worthTrade receivables grew 0.6% against revenue growth of -22.7% in FY26. Revenue may be being recognised ahead of collection.
rule: receivables growth > 1.3x sales growthShort-term borrowings of ₹116.06 cr against cash of ₹16.18 cr. Debt that must be refinanced within a year is comfortable only while lenders stay comfortable.
rule: cash < 0.5x short-term debtCompany's Claims vs Reality
We stress-test each claim against the filing's own data.
Filing confirms 94% volume share of India's thermal imaging exports between FY24 and FY26, with export sales across 12+ countries.
p.231, p.278Operating cash flow turned negative at ₹ -136.12 crore in FY25 and ₹ -63.22 crore in FY26 due to working capital days expanding to 517 days.
p.90, p.149Proprietary SWOT — Company-Specific
Strengths
- Proprietary full-stack Electro-Optical/Infrared IP portfolio free of ITAR export control restrictions.
- Global market leadership accounting for 94% volume share of India's thermal imaging export exports.
Weaknesses
- Significant working capital lock-up leading to negative operating cash flows in FY25 and FY26.
- High customer concentration with top customers contributing up to 88.13% of Q1 FY27 revenues.
Opportunities
- Expanding global military modernization budgets driving demand for night vision and AI-enabled target acquisition systems.
- Indian Defense Acquisition Procedure (DAP 2020) IDDM procurement mandates favoring domestic IP owners.
Threats (material, not boilerplate)
- Long gestation and delivery cycles in defense procurement leading to irregular revenue recognition and billing delays. risk_section
Why it matters: Extended procurement and testing cycles create cash flow volatility and unbilled inventory build-ups.
Allotment Status
Check your allotment on the registrar's portal → Registrar: KFin Technologies
Allotment is decided by the registrar, not by us and not by the exchange. In an oversubscribed retail book, allotment is by lottery, so a large application does not improve your odds beyond one lot. If money stays blocked after the refund date, the mandate expiry (30 Nov 2026) is the date to raise with your bank.
Analyst Q&A: Burning Questions
Facts from the filing. No recommendation — that layer arrives once our Research Analyst registration is live.
Will Tonbo Imaging India Limited receive any proceeds from the public offer?
No. The offer is 100% an Offer for Sale of up to 12,174,046 Equity Shares by Selling Shareholders including Promoters, CEAQ India, CEAQ Singapore, and Artiman entities. All proceeds go to the selling shareholders.
p.1, p.84, p.124What caused the drop in revenue and net profit in Fiscal 2026 compared to Fiscal 2025?
Consolidated revenue from operations decreased 22.69% to ₹ 362.65 crore in FY26 from ₹ 469.08 crore in FY25 due to timing of defense project shipments, while Restated PAT decreased to ₹ 50.88 crore from ₹ 72.76 crore.
p.322, p.430, p.433What is the reason for negative cash flow from operations in Fiscal 2025 and 2026?
Operating cash flows were negative at ₹ -136.12 crore in FY25 and ₹ -63.22 crore in FY26 due to working capital lock-up in raw material inventory (₹ 219.49 crore) and trade receivables (₹ 211.66 crore).
p.90, p.149, p.433Reading the Offer Structure
100% offer for sale — and the company does not appear to need the cash.
A high offer-for-sale share is not automatically a concern. On the disclosed numbers this company is profitable and not heavily borrowed, so the listing reads as an exit route for existing shareholders and a route to a public market rather than a funding exercise. Large, cash-generative companies routinely list this way.
What Earlier Investors Paid
Early capital takes real risk and is fairly rewarded for it — a large multiple built over many years is normal. What deserves a closer look is a steep step-up in a short window: a round priced cheaply only months before the offer.
| Shareholder | Priced at | When | vs IPO price |
|---|---|---|---|
| CEAQ India / CEAQ Singapore / Artiman Ventures | ₹2.00 | 2024-03-28 | 350.0x |
Prices are as stated in the filing’s allotment history and are not adjusted for later bonus issues or share splits. Where a company has issued bonus shares, the multiples above understate the true return and can even read as losses. Adjusting for that is on our list; until it is done we would rather show the raw disclosure and tell you its limits than publish a confident number that is wrong.
Lock-in Expiry Calendar
Shares held before the IPO cannot be sold immediately; they unlock in tranches. When a tranche unlocks, more shares become eligible to trade. Retail investors are frequently caught unaware by these dates. The schedule below follows from the listing date; quantities are shown only where the filing discloses them.
- 23 Apr 2028Minimum Promoters' Contribution18 months
- 23 Apr 2027Promoters' Shareholding in Excess of Minimum Contribution6 months
- 23 Apr 2027Entire Pre-Offer Equity Share Capital6 months
- 22 Nov 2026Anchor Investor Portion (50%)30 days
- 21 Jan 2027Anchor Investor Portion (50%)90 days
An unlock means more shares may be sold — not that they will be, and not that the price will move. We state the dates; what you do with them is your call.
Educational, grounded entirely in the company's filings (DRHP/RHP). Not investment advice. FinMinutes does not provide buy/sell recommendations.
